Drug Index


Mechanism :

Dupilumab is a human monoclonal IgG4 antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signalling by binding to the IL-4Ra subunit.

Indication :

  • Off-Label: Asthma, moderate to severe (uncontrolled)
  • Atopic dermatitis: Treatment of moderate to severe atopic dermatitis in adults

Contraindications :

Known hypersensitivity to dupilumab or any component of the formulation.

Dosing :

In patients aged ≥12 years with eosinophilic phenotype or PO corticosteroid dependent asthma.
400 mg SC once, then 200 mg once in 2 weeks.
Atopic dermatitis:
600 mg (i.e. two 300 mg injections) SC once, and then 300 mg SC every other week.

Adverse Effect :

Herpes simplex infection, Oral herpes, antibody development, injection site reaction, conjunctivitis.

Interaction :

Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab.
Vaccines (Live): Dupilumab may enhance the adverse/toxic effect of Vaccines.

Hepatic Dose :

No dosage adjustments are recommended.
03/21/2024 01:11:24 Dupilumab
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0